From the Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.
Clin Nucl Med. 2022 Sep 1;47(9):e605-e606. doi: 10.1097/RLU.0000000000004177. Epub 2022 Apr 5.
Dysregulation of the cyclin D-CDK4/6-INK4-RB pathway, which leads to uncontrolled cell proliferation, is frequently observed in breast cancer. Recently, 3 CDK4/6 inhibitors have been FDA approved as first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Despite promising clinical results, the metabolic response to treatment with these new drugs has not been elaborately demonstrated yet. Herein, we presented a patient with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who demonstrated a complete metabolic response on 18F-FDG PET/CT to treatment with a CDK4/6 inhibitor (ribociclib).
细胞周期蛋白 D-CDK4/6-INK4-RB 通路失调会导致细胞不受控制地增殖，这种情况在乳腺癌中经常发生。最近，3 种 CDK4/6 抑制剂已获得美国食品药品监督管理局批准，作为激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌患者的一线治疗药物。尽管这些新药的临床疗效令人鼓舞，但它们对治疗的代谢反应尚未得到详细证实。在此，我们报告了一例激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌患者，该患者在接受 CDK4/6 抑制剂（瑞博西利）治疗后，18F-FDG PET/CT 显示完全代谢反应。
